LAVA Therapeutics N.V. LVTX
1.74 0.00 (+0.00%)
At closeNov 28, 2025, 4:00 PM EST
1.74 Day range 1.74
52-week range unavailable
- YTD
- +82.97%
- 1 year
- +8.75%
News
defenseworld.net LAVA Therapeutics N.V. (NASDAQ:LVTX) Given Consensus Recommendation of “Reduce” by Analysts LAVA Therapeutics N.V. (NASDAQ: LVTX - Get Free Report) has received an average rating of "Reduce" from the seven research firms that are currently covering the firm, Marketbeat Ratings reports. One…
defenseworld.net Brokerages Set LAVA Therapeutics N.V. (NASDAQ:LVTX) PT at $2.69 LAVA Therapeutics N.V. (NASDAQ: LVTX - Get Free Report) has been assigned a consensus rating of "Reduce" from the seven brokerages that are currently covering the company, Marketbeat Ratings reports.…
gurufocus.com Robert Bruce's Strategic Moves: AT&T Inc. Sees a -1.41% Portfolio Impact Insightful Analysis of Robert Bruce (Trades, Portfolio)'s Third Quarter 2025 13F Filing Robert Bruce (Trades, Portfolio) recently submitted the 13F filing for
globenewswire.com LAVA Announces Exceeding Minimum Condition in Tender Offer and Intent to Delist from Nasdaq UTRECHT, The Netherlands, and PHILADELPHIA, Nov. 13, 2025 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (“LAVA”) (Nasdaq: LVTX) today announced that 22,877,463 of LAVA's common shares, representing…
globenewswire.com LAVA Therapeutics N.V. Shareholders are Reminded to Tender Shares for XOMA Royalty Transaction Before November 12, 2025 Deadline UTRECHT, The Netherlands and PHILADELPHIA, Nov. 10, 2025 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (“LAVA”) (NASDAQ: LVTX) today announced a reminder to LAVA shareholders related to the proposed…
prnewswire.com Shareholder Alert: The Ademi Firm investigates whether LAVA Therapeutics N.V. is obtaining a Fair Price for its Public Shareholders in the Amendment to the Purchase Agreement MILWAUKEE , Oct. 20, 2025 /PRNewswire/ --The Ademi Firm is investigating Lava (Nasdaq: LVTX) for possible breaches of fiduciary duty and other violations of law in its transaction with XOMA Royalty.…
globenewswire.com LAVA Therapeutics to Move Extraordinary General Meeting to Early November 2025 Additional time enables LAVA Therapeutics to address potential liabilities and confirm net cash to be delivered to Shareholders. LAVA Therapeutics and XOMA Royalty anticipate closing the announced…
benzinga.com 4 Biotech Stocks That Are Showing Weakness: Momentum Scores Fading Over The Past Week Several biotech stocks have seen their strength fade over the past week, with their Momentum scores in Benzinga's Edge Stock Rankings witnessing a significant decline.
globenewswire.com LAVA Reports Second Quarter 2025 Financial Results and Provides Corporate Update UTRECHT, The Netherlands, and PHILADELPHIA, Aug. 13, 2025 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (NASDAQ: LVTX, “LAVA,” or the “Company”), a clinical-stage immuno-oncology company historically…
prnewswire.com SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SCS, LVTX, ENZB on Behalf of Shareholders NEW YORK , Aug. 8, 2025 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches…
prnewswire.com SHAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of LAVA Therapeutics N.V. (NASDAQ: LVTX) NEW YORK , Aug. 7, 2025 /PRNewswire/ -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is…
businesswire.com LVTX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Lava Therapeutics N.V. Is Fair to Shareholders NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of LAVA Therapeutics N.V. (NASDAQ: LVTX) to XOMA Royalty Corporation is fair to LAVA…
globenewswire.com LAVA Reports First Quarter 2025 Financial Results, Provides Business Update UTRECHT, The Netherlands and PHILADELPHIA, May 14, 2025 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (NASDAQ: LVTX, “LAVA,” “the Company”), a clinical-stage immuno-oncology company focused on its…
globenewswire.com LAVA Therapeutics Granted Full Waiver for RVO Payment Obligation Exemption from the $5.1 million repayment obligation strengthens LAVA's balance sheet Underscores focus on cost curtailment and strategic option evaluation UTRECHT, The Netherlands and PHILADELPHIA,…
globenewswire.com LAVA Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update UTRECHT, The Netherlands and PHILADELPHIA, March 28, 2025 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (NASDAQ: LVTX, “LAVA,” “the Company”), a clinical-stage immuno-oncology company focused on…
benzinga.com Analyst Downgrades LAVA Therapeutics, Sees Pipeline Overhang On Tuesday, LAVA Therapeutics N.V. LVTX initiated a process to review strategic options.
globenewswire.com LAVA Doses First Patient in Phase 1 LAVA-1266 Study in Hematological Cancers UTRECHT, The Netherlands and PHILADELPHIA, Jan. 10, 2025 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (NASDAQ: LVTX, “LAVA,” “the Company”), a clinical-stage immuno-oncology company focused on…
globenewswire.com LAVA Reports Third Quarter 2024 Financial Results and Announces Pipeline Reprioritization and Cash Runway Extension into 2027 UTRECHT, The Netherlands and PHILADELPHIA, Dec. 10, 2024 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (NASDAQ: LVTX, “LAVA,” “the Company”), a clinical-stage immuno-oncology company focused on…
globenewswire.com LAVA Therapeutics to Participate in the H.C. Wainwright 26th Annual Global Investment Conference UTRECHT, The Netherlands and PHILADELPHIA, Sept. 03, 2024 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (NASDAQ: LVTX, “LAVA”), a clinical-stage immuno-oncology company focused on developing its…
globenewswire.com LAVA Reports Second Quarter 2024 Financial Results and Business Update UTRECHT, The Netherlands and PHILADELPHIA, Aug. 20, 2024 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (NASDAQ: LVTX, “LAVA,” “the Company”), a clinical-stage immuno-oncology company focused on…
benzinga.com Stocks That Hit 52-Week Lows On Wednesday On Wednesday, 479 stocks made new 52-week lows.- benzinga.com Benzinga's Top Ratings Upgrades, Downgrades For October 25, 2022 Upgrades
benzinga.com Why Aridis Pharmaceuticals Shares Plunged Around 30%; Here Are 81 Biggest Movers From Yesterday Gainers- benzinga.com Why LAVA Therapeutics Shares Are Trading Higher By 97%, Here Are 49 Stocks Moving In Monday's Mid-Day Session Gainers
benzinga.com Benzinga's Top Ratings Upgrades, Downgrades For September 15, 2022 Upgrades
benzinga.com Stocks That Hit 52-Week Lows On Friday On Friday, 422 stocks made new 52-week lows.
benzinga.com Stocks That Hit 52-Week Lows On Friday On Friday, 1043 companies hit new 52-week lows.
benzinga.com Stocks That Hit 52-Week Lows On Friday On Friday, 213 companies hit new 52-week lows.
benzinga.com Stocks That Hit 52-Week Lows On Wednesday Wednesday's session saw 784 companies set new 52-week lows.- benzinga.com 40 Biggest Movers From Friday Gainers
benzinga.com 60 Biggest Movers From Friday Gainers- benzinga.com 21 Stocks Moving in Monday's Pre-Market Session Gainers Exicure, Inc. (NASDAQ: XCUR) shares rose 41.5% to $1.91 in pre-market trading. Ipsen and Exicure signed an exclusive collaboration agreement to research, develop, and commercialize novel…
- benzinga.com 48 Biggest Movers From Yesterday Gainers Welbilt, Inc. (NYSE: WBT) shares surged 44.5% to close at $22.58 on Wednesday after The Middleby Corporation announced plans to acquire the company.
- benzinga.com 48 Biggest Movers From Thursday Gainers AeroCentury Corp. (NYSE: ACY) jumped 173.2% to close at $9.70 on Thursday. The company recently reported that it filed a petition for a Chapter 11 reorganization.